Ala T A, Perfetti P A, Frey W H
Alzheimer's Treatment and Research Center, Department of Neurology, Ramsey Clinic/St. Paul-Ramsey Medical Center, MN 55101-2595.
J Neuroimmunol. 1994 Aug;53(1):109-13. doi: 10.1016/0165-5728(94)90070-1.
During a study evaluating GM1 ganglioside as a possible treatment for Alzheimer's disease, two patients suffered immune responses that appeared to be limited to localized inflammation at the sites of the intramuscular GM1 injections. We determined that one patient's anti-GM1 IgM antibody titer rose from 1:400 to 1:3200 and her anti-GM1 IgG titer from < 1:50 to 1:400,000 during the immune response. The second patient's titer rose from < 1:50 to 1:3200 IgM and from 1:3200 to 1:400,000 IgG. These findings document that patients may experience acute rises in their anti-GM1 antibody levels in response to GM1 and that such rises may not necessarily cause significant acute clinical neuronal injury.
在一项评估神经节苷脂GM1作为阿尔茨海默病可能治疗方法的研究中，两名患者出现了免疫反应，这些反应似乎仅限于GM1肌肉注射部位的局部炎症。我们确定，在免疫反应期间，一名患者的抗GM1 IgM抗体滴度从1:400升至1:3200，其抗GM1 IgG抗体滴度从<1:50升至1:400,000。第二名患者的IgM滴度从<1:50升至1:3200，IgG滴度从1:3200升至1:400,000。这些发现证明，患者可能会因GM1而出现抗GM1抗体水平的急性升高，而且这种升高不一定会导致明显的急性临床神经元损伤。
